Get the Stockscreener App
26.79
1.90%
0.50
After Hours:
26.79
Tyra Biosciences Inc stock is traded at $26.79, with a volume of 793.77K.
It is up +1.90% in the last 24 hours and up +28.06% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$26.29
Open:
$26.28
24h Volume:
793.77K
Relative Volume:
1.97
Market Cap:
$1.43B
Revenue:
-
Net Income/Loss:
$-83.74M
P/E Ratio:
-16.64
EPS:
-1.61
Net Cash Flow:
$-64.98M
1W Performance:
+3.20%
1M Performance:
+28.06%
6M Performance:
+166.57%
1Y Performance:
+85.65%
1-Day Range:
$25.99
$27.66
1-Week Range:
$24.88
$27.66
52-Week Range:
$6.42
$27.66
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
26.79 | 1.40B | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Is Tyra Biosciences Inc a good long term investmentInsider Selling Patterns & Fast Growing Investment Ideas - earlytimes.in
Tyra Biosciences (NASDAQ:TYRA) Rating Increased to Hold at Wall Street Zen - MarketBeat
(TYRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
June Brings on Some Huge Insider Buying - AOL.com
Tyra Biosciences stock hits 52-week high at $26.36 By Investing.com - Investing.com Nigeria
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year HighTime to Buy? - MarketBeat
Tyra Biosciences stock hits 52-week high at $26.36 - Investing.com India
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛
Is Tyra Biosciences Inc. stock gaining market shareMACD Histogram Signals & Start Learning With Our Courses - bollywoodhelpline.com
Tyra Biosciences (NASDAQ:TYRA) Cut to Sell at Wall Street Zen - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Reaches New 52-Week HighHere's What Happened - MarketBeat
Does Tyra Biosciences (TYRA) Index Inclusion Mark a Turning Point in Its Institutional Story? - Yahoo Finance
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally - Yahoo Finance
(TYRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Tyra Biosciences director more sells $250k in shares By Investing.com - Investing.com South Africa
Tyra Biosciences director more sells $250k in shares - Investing.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Will Tyra Biosciences Inc. stock remain a Wall Street favorite2025 Winners & Losers & AI Powered Trade Plan Recommendations - Улправда
Tyra Biosciences (TYRA) Is Up 12.7% After Wedbush Highlights Pipeline Momentum And Leadership RefreshWhat's Changed - Sahm
Tyra Biosciences (NASDAQ:TYRA) Director Sells $250,000.00 in Stock - MarketBeat
Chmn More Sells 10,000 ($250K) Of Tyra Biosciences Inc [TYRA] - TradingView — Track All Markets
Can Tyra Biosciences Inc. stock surprise with earnings upsideJuly 2025 Patterns & Fast Exit and Entry Trade Guides - Улправда
Tyra Biosciences stock hits 52-week high at 24.05 USD By Investing.com - Investing.com Nigeria
Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week HighHere's What Happened - MarketBeat
Tyra Biosciences stock hits 52-week high at 24.05 USD - Investing.com
Analysis Recap: How Tyra Biosciences Inc. stock reacts to global recession fearsQuarterly Portfolio Report & Long-Term Safe Investment Ideas - Улправда
How Tyra Biosciences Inc. stock reacts to global recession fearsMarket Growth Report & AI Forecasted Entry and Exit Points - Улправда
Why Tyra Biosciences Inc. stock attracts high net worth investorsForecast Cut & Daily Profit Focused Stock Screening - Улправда
Growth Recap: Will Tyra Biosciences Inc. stock remain a Wall Street favoriteMarket Activity Summary & Low Risk Entry Point Guides - Улправда
Tyra Biosciences' Chief Discovery Officer Sells 8,000 Shares - TradingView — Track All Markets
Tyra Biosciences (TYRA) insider sells 8,000 shares in planned trade - Stock Titan
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Wedbush raises Tyra Biosciences stock price target to $37 on pipeline potential - Investing.com Canada
Assessing Tyra Biosciences (TYRA) Valuation Following Key Executive Hires to Support Advancing Clinical Pipeline - Sahm
Officer Bensen Files To Sell 8,000 Of Tyra Biosciences Inc [TYRA] - TradingView — Track All Markets
Understanding the Setup: (TYRA) and Scalable Risk - Stock Traders Daily
How Investors Are Reacting To Tyra Biosciences (TYRA) Bolstering Its Regulatory And Oncology Leadership - Sahm
Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month HighTime to Buy? - MarketBeat
Tyra Biosciences stock hits 52-week high at 22.83 USD By Investing.com - Investing.com Canada
Tyra Biosciences stock hits 52-week high at 22.83 USD - Investing.com
Tyra Biosciences, Inc. $TYRA Shares Acquired by Walleye Capital LLC - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Raised to "Hold" at Wall Street Zen - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Raised to “Hold” at Wall Street Zen - Defense World
What makes Tyra Biosciences Inc. stock attractive to growth funds2025 Pullback Review & Stock Portfolio Risk Management - Newser
Aug Mood: Why Tyra Biosciences Inc. stock attracts high net worth investorsJuly 2025 Chart Watch & High Win Rate Trade Tips - moha.gov.vn
Can Tyra Biosciences Inc. stock resist market sell offsJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Goldman Sachs initiates coverage of Tyra Biosciences stock with Early-Stage Biotech rating - Investing.com UK
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):